Listen
NERLYNX (neratinib) - Breast cancer
Opinions on drugs -
Posted on
May 30 2023
Reason for request
Inclusion
Inclusion.
Key points
Unfavourable opinion for reimbursement “in the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago”.
Role in the care pathway?
The Committee considers that NERLYNX (neratinib) has no role in the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.
Clinical Benefit
| Insufficient |
The clinical benefit of NERLYNX (neratinib) is insufficient in the marketing authorisation indication to justify public funding. |
Clinical Added Value
| Not applicable |
Documents
English version
Contact Us
Évaluation des médicaments
